Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Abstract Background Programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have remarkable clinical efficacy in the treatment of non-small cell lung cancer (NSCLC); however, the breakdown of immune escape causes a variety of immune-related adverse events (irAEs)...

Full description

Bibliographic Details
Main Authors: Xiaoying Sun, Raheleh Roudi, Ting Dai, Shangya Chen, Bin Fan, Hongjin Li, Yaqiong Zhou, Min Zhou, Bo Zhu, Chengqian Yin, Bin Li, Xin Li
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Oncology
Programmed cell death protein-1
Programmed cell death ligand 1
Inhibitor
Immune-related adverse event
Online Access:http://link.springer.com/article/10.1186/s12885-019-5701-6

Internet

http://link.springer.com/article/10.1186/s12885-019-5701-6

Similar Items